Results of the phase 1/2 first-in-human clinical trials testing Revumenib and Ziftomenib in patients with MLL1-r and NPM1-mut acute leukemias revealed promising outcomes with an over 30% rate of complete remission (19, 20). The gene discussed is KMT2A; the disease is acute leukemia.